Get the Stockscreener App
1.69
0.00%
0.00
Pre-market:
1.71
0.02
+1.18%
Pepgen Inc stock is traded at $1.69, with a volume of 1.65M.
It is up +0.00% in the last 24 hours and down -68.26% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$1.69
Open:
$1.73
24h Volume:
1.65M
Relative Volume:
1.33
Market Cap:
$116.80M
Revenue:
-
Net Income/Loss:
$-89.66M
P/E Ratio:
-0.6982
EPS:
-2.4205
Net Cash Flow:
$-81.90M
1W Performance:
+1.20%
1M Performance:
-68.26%
6M Performance:
-63.10%
1Y Performance:
+53.64%
1-Day Range:
$1.68
$1.80
1-Week Range:
$1.57
$1.80
52-Week Range:
$1.01
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
1.69 | 113.35M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
Biotech Firm PepGen Receives 'Moderate Buy' Rating from Analysts - National Today
PepGen: Modest FREEDOM2 Efficacy, Regulatory Overhang, and Competitive Pressures Underscore Sell Rating - TipRanks
Signal Recap: Should I set a stop loss on PepGen Inc2026 Pullback Review & Technical Confirmation Alerts - baoquankhu1.vn
PepGen crashes after mid-stage trial data for muscle disorder therapy - MSN
PepGen team joins Kansas City event to drive myotonic dystrophy research discussions - Traders Union
Rate Cut: Does PepGen Inc have declining or rising EPSAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
PepGen joins MyotonicStrong conference to present clinical progress - Traders Union
Top 3 Health Care Stocks Which Could Blast Off This Quarter - Benzinga
Retail Trends: Is PepGen Inc forming a breakout pattern2026 Chart Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Published on: 2026-04-07 21:04:49 - baoquankhu1.vn
PEPG.O Technical Analysis & Stock Price Forecast - Intellectia AI
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
PEPG Technical Analysis & Stock Price Forecast - Intellectia AI
PepGen stock plunges 26% on FDA partial clinical hold - Investing.com
PepGen Reports Encouraging Phase II FREEDOM2 DM1 Data at 5 mg/kg; 10 mg/kg Cohort Underway - National Today
Wedbush Maintains PepGen (PEPG) Outperform Recommendation - MSN
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com
Scholar Rock To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Assay what? Eyes on Pepgen’s vim-sapping DM1 phase II - BioWorld MedTech
Buy Rating on PepGen: DM1 Program De-Risked by Stronger Underlying Biology and Upside from Higher-Dose Cohorts - TipRanks
PEPG: FREEDOM2's 5 mg/kg cohort showed promising safety and efficacy, supporting dose escalation - TradingView — Track All Markets
MACD Signal: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAR2026 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
PepGen Shares Fall After Data From Ongoing Phase 2 Study for Myotonic Dystrophy Type 1 Patients - MarketScreener
PepGen's 5 mg/kg Data Outlier: Is This a Prelude to a 10 mg/kg Comeback or Evidence of a Failed Strategy? - Bitget
PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief - Seeking Alpha
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease - BioSpace
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
A Quick Look at Today's Ratings for PepGen(PEPG.US), With a Forecast Between $3 to $20 - news.futunn.com
Why PEPG, SGMO, PHR are among top premarket losers today - MSN
Wedbush Cuts Price Target on PepGen to $5 From $9, Keeps Outperform Rating - marketscreener.com
Why Is PepGen Stock Sinking Tuesday? - Benzinga
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
PepGen Inc. (PEPG) Discusses Topline Results From Lowest Dose MAD Cohort in Phase II FREEDOM2 Study With Favorable Safety, Splicing and vHOT DataSlideshow (NASDAQ:PEPG) 2026-03-31 - Seeking Alpha
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data - BioSpace
PepGen reports ‘promising’ topline results from MAD cohort - TipRanks
PepGen stock tumbles 44% on disappointing trial results By Investing.com - Investing.com Canada
Movement Recap: Should I set a stop loss on PepGen Inc2026 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
PepGen Reports Early Phase 2 FREEDOM2-DM1 Topline Data - TipRanks
PepGen reports mixed results from DM1 trial, 10mg cohort ongoing By Investing.com - Investing.com Australia
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView — Track All Markets
[8-K] PepGen Inc. Reports Material Event - Stock Titan
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):